GLP-1
Sub-Areas to GLP-1:
Hypoglycemia
(1)
Glucagon Suppression
(1)
Preproglucagon Gene
(1)
(Journal Article): Anti-diabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S
IN:
N Engl J Med
1992; 326:1316-1322
Impact Factor(s) of N Engl J Med: 44.016 (2005), 38.57 (2004), 34.833 (2003), 29.065 (2001)
ABSTRACT:
BACKGROUND. Glucagon-like peptide-1 (7-36) amide (glucagon-like insulinotropic peptide, or GLIP) is a gastrointestinal peptide that potentiates the release of insulin in physiologi...
Click HERE for details
(Journal Article): Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF
IN:
Diabetes Care
1992; 15:270-276
Impact Factor(s) of Diabetes Care: 7.071 (2004), 7.501 (2003), 5.477 (2002), 5.404 (2001)
ABSTRACT:
OBJECTIVE--Whether glucagonlike peptide-I-(7-37) (GLP-I-[7-37]), a naturally occurring intestinal peptide, is insulinotropic in nondiabetic and non-insulin-dependent (type II) diab...
Click HERE for details
(Journal Article): Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W
IN:
Diabetologia
1993; 36(8):741-744
Impact Factor(s) of Diabetologia: 5.583 (2004), 5.689 (2003), 5.136 (2002), 6.299 (2001)
ABSTRACT:
Glucagon-like peptide 1 (GLP-1) (7-36 amide) is a physiological incretin hormone that is released after nutrient intake from the lower gut and stimulates insulin secretion at eleva...
Click HERE for details
(Journal Article): Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential.
Holst JJ
IN:
Curr Med Chem
1999; 6(11):1005-1017
Impact Factor(s) of Curr Med Chem: 4.382 (2004), 4.409 (2003), 4.966 (2002), 5.76 (2001)
ABSTRACT:
Glucagon-like peptide-1 (GLP-1) is an insulinotropic hormone secreted from endocrine cells in the gut mucosa in response to meal ingestion. It is an important incretin hormone; mic...
Click HERE for details
(Journal Article): The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ, Nauck MA
IN:
Curr Opin Investig Drugs
2004; 5(4):402-410
ABSTRACT:
The incretin hormone glucagon-like peptide 1 (GLP-1) has a promising potential for the treatment of type 2 diabetes due to its glucose-dependent insulinotropic and glucagonostatic ...
Click HERE for details
(Journal Article): Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.
DeFronzo RA
IN:
Diabetes
1988; 37(6):667-687
Impact Factor(s) of Diabetes: 8.848 (2004), 8.298 (2003), 8.256 (2002), 7.7 (2001)
ABSTRACT:
n.a.
Click HERE for details
(Journal Article): A role for glucagon-like peptide-1 in the central regula-tion of feeding.
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR
IN:
Nature
1996; 379(6560):69-72
Impact Factor(s) of Nature: 29.273 (2005), 32.182 (2004), 30.979 (2003), 30.432 (2002), 27.955 (2001)
ABSTRACT:
The sequence of glucagon-like peptide-1 (7-36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role. We have...
Click HERE for details
(Journal Article): Normalization of glucose concen-trations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA
IN:
J Clin Endocrinol Metab
2003; 88(6):2719-2725
Impact Factor(s) of J Clin Endocrinol Metab: 5.778 (2004), 5.873 (2003), 5.16 (2001)
ABSTRACT:
The effects of different i.v. doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and gastric emptying were compared in patients with type 2 diabetes. Twelve patients w...
Click HERE for details
(Journal Article): Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
Zander M, Madsbad S, Madsen JL, Holst JJ
IN:
Lancet
2002; 359(9309):824-830
Impact Factor(s) of Lancet: 23.407 (2005), 21.713 (2004), 18.316 (2003), 15.397 (2002), 13.251 (2001)
ABSTRACT:
BACKGROUND: Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this pe...
Click HERE for details
|
| Contribute
to this subject area!
|
|
|
